| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Cloflucarban targets bacterial cell membranes, interfering with bacterial cell membrane function and affecting membrane permeability, thereby inhibiting normal bacterial metabolism and proliferation. It has also been identified as an activator of the PINK1-Parkin pathway, which is involved in mitochondrial quality control. Cloflucarban simultaneously inhibits mitochondrial complexes III and V, and this dual inhibition activates the PINK1-Parkin pathway.
|
|---|---|
| ln Vitro |
In vitro, Cloflucarban demonstrates antibacterial activity against a range of bacteria. It has been identified as a novel pathway activator that simultaneously inhibits mitochondrial complexes III and V. RNA interference (RNAi) confirmed that the dual inhibition of these complexes activates the PINK1-Parkin pathway. The compound's antibacterial and pathway-activating activities have been characterized in various in vitro assays.
|
| ln Vivo |
In vivo, Cloflucarban is used as a disinfectant and antibacterial agent in consumer products such as soaps and deodorants. Its antibacterial properties help to control microbial growth on the skin. The compound has been studied for its effects on the PINK1-Parkin pathway in cellular models. Specific in vivo data regarding systemic effects are limited, as the compound is primarily used topically.
|
| Enzyme Assay |
In vitro antibacterial assays for Cloflucarban typically use broth microdilution or agar diffusion methods according to CLSI guidelines. Bacterial cultures (e.g., Staphylococcus aureus, Escherichia coli) are prepared at a standardized inoculum and incubated with varying concentrations of the compound. Minimum inhibitory concentrations (MICs) are determined as the lowest concentration that inhibits visible bacterial growth. For PINK1-Parkin pathway activation, mitochondrial complex activity assays are performed using isolated mitochondria or cell lysates.
|
| Cell Assay |
Cellular assays for antibacterial activity typically use mammalian cell lines for cytotoxicity assessment and bacterial cell cultures for antibacterial activity. For PINK1-Parkin pathway studies, cells (e.g., SH-SY5Y or HeLa cells) are treated with Cloflucarban, and Parkin translocation to mitochondria is assessed by immunofluorescence microscopy. Mitochondrial membrane potential is measured using fluorescent dyes (e.g., JC-1 or TMRM). Mitochondrial complex activities are measured using specific substrates and inhibitors.
|
| Animal Protocol |
In vivo animal studies for antibacterial efficacy would typically use topical infection models or systemic infection models in rodents. However, as Cloflucarban is primarily used as a topical antiseptic in consumer products, extensive in vivo efficacy studies are limited. For PINK1-Parkin pathway studies, animal models of mitochondrial dysfunction or Parkinson's disease may be used. Specific protocols are available from published studies on the compound's pathway-activating effects.
|
| ADME/Pharmacokinetics |
Cloflucarban is primarily used topically as a disinfectant and antibacterial agent in soaps and deodorants. Systemic absorption following topical application is minimal. When absorbed, the compound would be metabolized in the liver and excreted via the kidneys. Detailed PK parameters are limited, as the compound is not used as a systemic therapeutic agent.
|
| Toxicity/Toxicokinetics |
Cloflucarban is generally considered safe for topical use in consumer products. It has low toxicity when applied to the skin, with no significant systemic toxicity reported. Skin irritation or sensitization may occur in sensitive individuals. The compound has been used for decades in soaps and deodorants, and its safety profile is well-established for topical applications.
|
| Additional Infomation |
Halocarban is a phenylurea compound with the structure urea, substituted at positions 1 and 3 with 4-chlorophenyl and 4-chloro-3-trifluoromethylphenyl, respectively. Due to its antibacterial properties, it is commonly used in deodorants and soaps. It is an antibacterial agent. It belongs to the phenylurea and monochlorobenzene classes of compounds. It contains a trifluoromethyl group. Chlorocarban is a synthetic carbanelline compound with preservative activity. Chlorocarban is used as a disinfectant and is found in antibacterial soaps and deodorants.
Cloflucarban (Halocarban) is a synthetic carbanilide compound with antiseptic and antibacterial activity. It is commonly used in deodorants and soaps due to its antibacterial properties. The compound belongs to the phenylurea and monochlorobenzene classes and contains a trifluoromethyl group. It has also been identified as a novel activator of the PINK1-Parkin pathway by inhibiting mitochondrial complexes III and V. Cloflucarban is available for research use and has been studied for its pathway-activating effects. |
| Molecular Formula |
C14H9CL2F3N2O
|
|---|---|
| Molecular Weight |
349.1342
|
| Exact Mass |
348.004
|
| CAS # |
369-77-7
|
| PubChem CID |
9719
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.536g/cm3
|
| Boiling Point |
328.8ºC at 760mmHg
|
| Flash Point |
152.7ºC
|
| Index of Refraction |
1.62
|
| LogP |
5.802
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
22
|
| Complexity |
387
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC=1C=CC(=CC1C(F)(F)F)NC(NC2=CC=C(Cl)C=C2)=O
|
| InChi Key |
ZFSXZJXLKAJIGS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H9Cl2F3N2O/c15-8-1-3-9(4-2-8)20-13(22)21-10-5-6-12(16)11(7-10)14(17,18)19/h1-7H,(H2,20,21,22)
|
| Chemical Name |
1-(4-chlorophenyl)-3-[4-chloro-3-(trifluoromethyl)phenyl]urea
|
| Synonyms |
Halocarban; Irgasan CF3; Cloflucarban
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~358.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8643 mL | 14.3213 mL | 28.6426 mL | |
| 5 mM | 0.5729 mL | 2.8643 mL | 5.7285 mL | |
| 10 mM | 0.2864 mL | 1.4321 mL | 2.8643 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
